[Cyclooxygenase-2 inhibitors and the ethics of research].
Gherardi
Carlos R
CR
D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D017277:Drug Approval; D032984:Ethics, Research; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects; D007783:Lactones / Q000009:adverse effects; D011720:Pyrazoles / Q000009:adverse effects; D013449:Sulfonamides / Q000009:adverse effects; D013450:Sulfones / Q000009:adverse effects; D000096926:Benzenesulfonamides
D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors; D007555:Isoxazoles; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; C406224:valdecoxib; D000096926:Benzenesulfonamides